Eyebot wants to make getting a prescription for glasses as fast as ordering a coffee.

REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...

Inflammasome Therapeutics' K8 slowed GA lesion growth 54% and showed a 4.0-letter vision advantage at six months in Phase 2. Phase 3 planned.

Results point to potential to restore vision with drugs, non-invasively, reversibly, via a mechanism that is independent to ...

Dompé advances cenegermin-bkbj into Phase 3 for NAION, a rapid vision-loss condition with no FDA-approved treatment options.

D-150 gene therapy enters pivotal Wet-AMD/DME trials, cutting injections up to 89%. Click for this FDMT update.

Blinding diseases caused by the degeneration of photoreceptors, such as age-related macular degeneration (AMD) and retinitis ...

Roughly one in five Americans aged 70 and older is living with both hearing loss and vision loss at the same time, according ...

View-tolerant identity recognition in humans depends on the stable identity cues provided by horizontal facial information.

SNU Eye Clinic explains why early cataract symptoms are often mistaken for presbyopia and why comprehensive eye ...

Blinding diseases caused by the degeneration of photoreceptors, such as age-related macular degeneration (AMD) and retinitis ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter ...